Furthermore, when HCC cells exposed to PDGFRβ-targeted siRNA, the activity of sorafenib against rapamycin-induced AKT phosphorylation was attenuated evidently (Fig. 3D), suggesting that this inhibition role on AKT phosphorylation may be PDGFRβ-dependent. This evidence concerns the gene AKT1 and hepatocellular carcinoma.